300723 一品红
已收盘 12-15 15:00:00
资讯
新帖
简况
一品红最新公告：拟最高或达15亿美元出售参股公司美国Arthrosi公司13.45%股权
证券之星 · 19:49
一品红最新公告：拟最高或达15亿美元出售参股公司美国Arthrosi公司13.45%股权
一品红（300723）披露关于参股公司美国Arthrosi被并购的提示性公告，12月15日股价下跌20.0%
证券之星 · 17:57
一品红（300723）披露关于参股公司美国Arthrosi被并购的提示性公告，12月15日股价下跌20.0%
12月15日一品红（300723）龙虎榜数据：机构净卖出7066.53万元，北向资金净买入520.1万元
证券之星 · 17:52
12月15日一品红（300723）龙虎榜数据：机构净卖出7066.53万元，北向资金净买入520.1万元
异动快报：一品红（300723）12月15日9点40分触及跌停板
证券之星 · 09:41
异动快报：一品红（300723）12月15日9点40分触及跌停板
一品红最新公告：参股公司美国Arthrosi拟被并购
证券之星 · 12-14 16:59
一品红最新公告：参股公司美国Arthrosi拟被并购
一品红最新公告：芩香清解口服液获批国家中药二级保护品种
证券之星 · 12-14 16:40
一品红最新公告：芩香清解口服液获批国家中药二级保护品种
一品红(300723.SZ)子公司获左氧氟沙星口服溶液注册证书
智通财经 · 12-11
一品红(300723.SZ)子公司获左氧氟沙星口服溶液注册证书
一品红（300723）披露受让控股子公司少数股东部分股权暨关联交易的进展公告，12月8日股价上涨0.75%
证券之星 · 12-08
一品红（300723）披露受让控股子公司少数股东部分股权暨关联交易的进展公告，12月8日股价上涨0.75%
一品红(300723)11月30日股东户数2.04万户，较上期减少1.73%
证券之星 · 12-02
一品红(300723)11月30日股东户数2.04万户，较上期减少1.73%
一品红最新公告：全资子公司获得复方聚乙二醇（3350）电解质散注册证书
证券之星 · 11-28
一品红最新公告：全资子公司获得复方聚乙二醇（3350）电解质散注册证书
一品红(300723.SZ)：艾司奥美拉唑镁肠溶干混悬剂获注册证书
智通财经 · 11-28
一品红(300723.SZ)：艾司奥美拉唑镁肠溶干混悬剂获注册证书
一品红(300723.SZ)：己酮可可碱缓释片获注册证书
智通财经 · 11-28
一品红(300723.SZ)：己酮可可碱缓释片获注册证书
11月25日一品红涨9.49%，广发医疗保健股票A基金重仓该股
证券之星 · 11-25
11月25日一品红涨9.49%，广发医疗保健股票A基金重仓该股
一品红（300723）披露全资子公司获得重酒石酸利斯的明口服溶液注册证书，11月24日股价上涨1.36%
证券之星 · 11-24
一品红（300723）披露全资子公司获得重酒石酸利斯的明口服溶液注册证书，11月24日股价上涨1.36%
一品红(300723.SZ)：重酒石酸利斯的明口服溶液获注册证书
智通财经 · 11-24
一品红(300723.SZ)：重酒石酸利斯的明口服溶液获注册证书
一品红（300723）披露调整公司治理结构并修订《公司章程》议案获通过，11月18日股价下跌1.54%
证券之星 · 11-18
一品红（300723）披露调整公司治理结构并修订《公司章程》议案获通过，11月18日股价下跌1.54%
11月13日一品红涨6.87%，广发医疗保健股票A基金重仓该股
证券之星 · 11-13
11月13日一品红涨6.87%，广发医疗保健股票A基金重仓该股
股市必读：一品红(300723)股东户数2.07万户，较上期增加9.42%
证券之星 · 11-06
股市必读：一品红(300723)股东户数2.07万户，较上期增加9.42%
一品红：截止至2025年10月31日股东总户数20,721户
证券之星 · 11-05
一品红：截止至2025年10月31日股东总户数20,721户
一品红（300723）2025年三季报简析：亏损收窄，三费占比上升明显
证券之星 · 10-31
一品红（300723）2025年三季报简析：亏损收窄，三费占比上升明显
暂无数据
公司概况
公司名称：
一品红药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2017-11-16
主营业务：
一品红药业集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是化学药(含原料药和制剂)、特色中成药等。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。
发行价格：
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":37.32,"timestamp":1765782192000,"preClose":46.65,"halted":0,"volume":16847300,"delay":0,"changeRate":-0.2,"floatShares":418000000,"shares":451999999,"eps":-0.9511,"marketStatus":"已收盘","change":-9.33,"latestTime":"12-15 15:00:00","open":37.32,"high":38,"low":37.32,"amount":630000000,"amplitude":0.0146,"askPrice":37.32,"askSize":17521,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.9511,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"adjPreClose":46.65,"symbolType":"stock","openAndCloseTimeList":[[1765762200000,1765769400000],[1765774800000,1765782000000]],"highLimit":51.32,"lowLimit":41.99,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":12.04,"roa":"--","roe":"--","epsLYR":-1.1956,"committee":0,"marketValue":16857000000,"turnoverRate":0.0403,"status":1,"floatMarketCap":15587000000},"requestUrl":"/m/hq/s/300723/tweets","defaultTab":"tweets","newsList":[{"id":"2591643058","title":"一品红最新公告：拟最高或达15亿美元出售参股公司美国Arthrosi公司13.45%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643058","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591643058?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:49","pubTimestamp":1765799387,"startTime":"0","endTime":"0","summary":"一品红公告称，公司拟通过全资子公司出售参股公司美国Arthrosi Therapeutics, Inc. 13.45%的股权，交易对方为瑞典Swedish Orphan Biovitrum AB下属全资子公司Sobi US Holding Corp.。交易总价最高或达15亿美元，包括9.5亿美元首付款和最高5.5亿美元的里程碑付款。交易完成后，公司将不再持有Arthrosi股权。本次交易尚需提请公司股东会审议批准。预计本次出让股权将对公司产生积极影响，最终对公司利润的影响金额以会计师审计确认后的数据为准。回购价格不超过70元/股，用于维护公司价值及股东权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500029535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2591175936","title":"一品红（300723）披露关于参股公司美国Arthrosi被并购的提示性公告，12月15日股价下跌20.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591175936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591175936?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:57","pubTimestamp":1765792640,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，一品红报收于37.32元，较前一交易日下跌20.0%，最新总市值为168.57亿元。公司于近日发布关于参股公司美国Arthrosi被并购的提示性公告。公告显示，一品红药业集团股份有限公司通过全资子公司持有美国Arthrosi公司13.45%股权。Sobi美国拟以9.5亿美元首付款及最高5.5亿美元里程碑付款收购Arthrosi 100%股权，交易需经Arthrosi股东会批准。公司持有AR882在中国地区100%市场权益，并优先拥有全球生产供应权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500023337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2591612216","title":"12月15日一品红（300723）龙虎榜数据：机构净卖出7066.53万元，北向资金净买入520.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612216?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:52","pubTimestamp":1765792373,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年12月15日公布的交易公开信息显示，一品红因日跌幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年12月15日收盘，一品红报收于37.32元，下跌20.0%，跌停，换手率4.03%，成交量16.85万手，成交额6.3亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出7066.53万元，北向资金合计净买入520.1万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500022819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2591695143","title":"异动快报：一品红（300723）12月15日9点40分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2591695143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591695143?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:41","pubTimestamp":1765762863,"startTime":"0","endTime":"0","summary":"证券之星12月15日盘中消息，9点40分一品红（300723）触及跌停板。其所属行业化学制药目前下跌。领涨股为花园生物。该股为中药，疫苗，创新药概念热股。12月12日的资金流向数据方面，主力资金净流出3176.66万元，占总成交额9.66%，游资资金净流入2041.87万元，占总成交额6.21%，散户资金净流入1134.8万元，占总成交额3.45%。近5日资金流向一览见下表：一品红主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500002448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2591650759","title":"一品红最新公告：参股公司美国Arthrosi拟被并购","url":"https://stock-news.laohu8.com/highlight/detail?id=2591650759","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591650759?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:59","pubTimestamp":1765702770,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司参股的美国Arthrosi Therapeutics,Inc.（简称：“Arthrosi”）收到Sobi美国发出的相关协议条款，Sobi美国拟以9.5亿美元首付款（折合人民币约67.13亿元），以及最高达5.5亿美元（折合人民币约38.87亿元）的临床、注册和销售里程碑付款收购Arthrosi 100%股权。公司通过全资子公司瑞腾生物(香港)有限公司持有Arthrosi 13.45%的股权。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121400005009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2591650108","title":"一品红最新公告：芩香清解口服液获批国家中药二级保护品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2591650108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591650108?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:40","pubTimestamp":1765701614,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，12月12日，国家药品监督管理局网站发布了《中药保护品种公告（第32号）》，国家药品监督管理局批准公司全资子公司一品红生物医药有限公司的芩香清解口服液为国家中药二级保护品种，芩香清解口服液用于疏风解热，清泻里热，解毒利咽，在临床上主要用于小儿上呼吸道感染属表里俱热证。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121400003924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2590759897","title":"一品红(300723.SZ)子公司获左氧氟沙星口服溶液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590759897","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590759897?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:44","pubTimestamp":1765439064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于左氧氟沙星口服溶液的《药品注册证书》。左氧氟沙星是第三代喹诺酮类药物，主要作用机制为抑制细菌DNA旋转酶的活性，阻碍细菌DNA的复制。它具有抗菌谱广、抗菌作用强的特点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"一品红(300723.SZ)子公司获左氧氟沙星口服溶液注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2589359970","title":"一品红（300723）披露受让控股子公司少数股东部分股权暨关联交易的进展公告，12月8日股价上涨0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589359970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589359970?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:20","pubTimestamp":1765203637,"startTime":"0","endTime":"0","summary":"公司近日发布关于受让控股子公司少数股东部分股权暨关联交易的进展公告。公告显示，一品红药业集团股份有限公司于2025年5月16日召开董事会及监事会会议，并于2025年7月1日召开临时股东大会，审议通过公司全资子公司瑞奥生物以自有资金680万美元受让控股子公司广州瑞安博少数股东Arthrosi 15.25%股权的议案。目前，广州瑞安博已完成工商变更登记，瑞奥生物现持有其100.00%股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800035005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2588303992","title":"一品红(300723)11月30日股东户数2.04万户，较上期减少1.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588303992","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588303992?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:47","pubTimestamp":1764668828,"startTime":"0","endTime":"0","summary":"证券之星消息，近日一品红披露，截至2025年11月30日公司股东户数为2.04万户，较10月31日减少358.0户，减幅为1.73%。在化学制药行业个股中，一品红股东户数低于行业平均水平，截至11月30日，化学制药行业平均股东户数为3.45万户。从股价来看，2025年10月31日至2025年11月30日，一品红区间跌幅为9.4%，在此期间股东户数减少358.0户，减幅为1.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200026610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2586788110","title":"一品红最新公告：全资子公司获得复方聚乙二醇（3350）电解质散注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586788110","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586788110?lang=zh_cn&edition=full","pubTime":"2025-11-28 17:41","pubTimestamp":1764322909,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司全资子公司广州一品红制药有限公司收到国家药品监督管理局核准签发的复方聚乙二醇（3350）电解质散的《药品注册证书》。该药品适用于治疗1岁至11岁儿童慢性便秘和粪便嵌塞，是国家医保乙类产品。此次获批丰富了公司产品管线，增强了在儿童药领域的竞争力，但同时也存在销售不达预期的风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800025801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2586202893","title":"一品红(300723.SZ)：艾司奥美拉唑镁肠溶干混悬剂获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586202893","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586202893?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:20","pubTimestamp":1764318023,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于艾司奥美拉唑镁肠溶干混悬剂的《药品注册证书》。艾司奥美拉唑是一种质子泵抑制剂，是奥美拉唑的S-异构体，通过特异性地抑制胃壁细胞H+-K+ATP酶而阻断胃酸分泌的最后步骤。艾司奥美拉唑在胃壁细胞的酸性环境中转化为活性成分，对基础胃酸分泌和受刺激后的胃酸分泌均产生抑制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2586204290","title":"一品红(300723.SZ)：己酮可可碱缓释片获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586204290","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586204290?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:17","pubTimestamp":1764317863,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)公告，公司全资子公司广州市联瑞制药有限公司于近日收到国家药品监督管理局核准签发的关于己酮可可碱缓释片的《药品注册证书》。己酮可可碱缓释片适应症为：周围性血管疾病，包括间歇性跛行和静息疼痛。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"一品红(300723.SZ)：己酮可可碱缓释片获注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2586674447","title":"11月25日一品红涨9.49%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586674447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586674447?lang=zh_cn&edition=full","pubTime":"2025-11-25 15:38","pubTimestamp":1764056334,"startTime":"0","endTime":"0","summary":"证券之星消息，11月25日一品红涨9.49%，收盘报53.76元，换手率3.75%，成交量15.64万手，成交额8.33亿元。重仓一品红的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共44家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为51.85亿元，最新净值1.8901，较上一交易日上涨1.8%，近一年上涨15.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500017508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2585846498","title":"一品红（300723）披露全资子公司获得重酒石酸利斯的明口服溶液注册证书，11月24日股价上涨1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585846498","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585846498?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:21","pubTimestamp":1763994113,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，一品红报收于49.1元，较前一交易日上涨1.36%，最新总市值为221.78亿元。该股当日开盘48.2元，最高50.31元，最低48.2元，成交额达2.61亿元，换手率为1.27%。公司近日发布公告称，其全资子公司广州一品红制药有限公司收到国家药品监督管理局签发的重酒石酸利斯的明口服溶液《药品注册证书》。药品批准文号有效期至2030年11月17日。未来生产和销售可能受市场环境等因素影响，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2585450876","title":"一品红(300723.SZ)：重酒石酸利斯的明口服溶液获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2585450876","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585450876?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:19","pubTimestamp":1763975948,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于重酒石酸利斯的明口服溶液的《药品注册证书》。根据核准的说明书，重酒石酸利斯的明口服溶液适应症为：用于治疗轻、中度阿尔茨海默型痴呆的症状。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"一品红(300723.SZ)：重酒石酸利斯的明口服溶液获注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2584955558","title":"一品红（300723）披露调整公司治理结构并修订《公司章程》议案获通过，11月18日股价下跌1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584955558?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:25","pubTimestamp":1763475924,"startTime":"0","endTime":"0","summary":"根据公司近日发布的公告，一品红药业集团股份有限公司于2025年11月18日召开2025年第三次临时股东大会，会议审议通过了《关于调整公司治理结构并修订<公司章程>的议案》及逐项审议《关于修订、制定公司部分管理制度的议案》共11项议案。其中，《关于调整公司治理结构并修订<公司章程>的议案》获高票通过，其余议案虽获通过，但中小股东反对比例较高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2583552572","title":"11月13日一品红涨6.87%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583552572","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583552572?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:34","pubTimestamp":1763022882,"startTime":"0","endTime":"0","summary":"证券之星消息，11月13日一品红涨6.87%，收盘报51.46元，换手率3.44%，成交量14.35万手，成交额7.31亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共44家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为51.85亿元，最新净值1.9048，较上一交易日上涨0.85%，近一年上涨9.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300027766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2581777777","title":"股市必读：一品红(300723)股东户数2.07万户，较上期增加9.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581777777","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581777777?lang=zh_cn&edition=full","pubTime":"2025-11-06 01:16","pubTimestamp":1762362976,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘，一品红报收于50.13元，下跌2.94%，换手率2.15%，成交量8.97万手，成交额4.51亿元。当日关注点来自交易信息汇总：11月5日主力资金净流出1637.29万元，显示主力短期谨慎态度。来自股本股东变化：截至2025年10月31日，公司股东户数环比增长9.42%，户均持股数量下降至2.18万股。股本股东变化股东户数变动近日一品红披露，截至2025年10月31日公司股东户数为2.07万户，较9月30日增加1784.0户，增幅为9.42%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600000994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2581791434","title":"一品红：截止至2025年10月31日股东总户数20,721户","url":"https://stock-news.laohu8.com/highlight/detail?id=2581791434","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581791434?lang=zh_cn&edition=full","pubTime":"2025-11-05 08:27","pubTimestamp":1762302444,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止至2025年10月20日收盘公司股东人数为多少，谢谢！一品红回复：尊敬的投资者您好，感谢您对公司的关注。截止至2025年10月31日，公司股东总户数20,721户。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500005374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2579610126","title":"一品红（300723）2025年三季报简析：亏损收窄，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2579610126","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579610126?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:52","pubTimestamp":1761864779,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期一品红发布2025年三季报。截至本报告期末，公司营业总收入8.14亿元，同比下降34.35%，归母净利润-1.36亿元，同比上升44.8%。按单季度数据看，第三季度营业总收入2.3亿元，同比下降29.66%，第三季度归母净利润-6254.1万元，同比上升78.65%。本报告期一品红三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达56.21%。），公司上市来已有年报7份，亏损年份1次，需要仔细研究下有无特殊原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100010148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765803781729,"stockEarnings":[{"period":"1week","weight":-0.0283},{"period":"1month","weight":-0.0312},{"period":"3month","weight":-0.2518},{"period":"6month","weight":-0.186},{"period":"1year","weight":1.2005},{"period":"ytd","weight":1.7345}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20363人(较上一季度减少1.73%)","perCapita":"20511股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":" 一品红药业集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是化学药(含原料药和制剂)、特色中成药等。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}